Document Detail


Evidence-based assessment of pregnancy outcome after sumatriptan exposure.
MedLine Citation:
PMID:  12005279     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Assessment of best available evidence for tolerability of sumatriptan after inadvertent exposure during pregnancy. BACKGROUND: Migraine's demography suggests that inadvertent exposure to acute therapies is likely during the earliest undiagnosed stages of pregnancy. The tolerability of such therapies under these conditions is not amenable to clinical trial for ethical reasons. In the United States, sumatriptan is currently labeled pregnancy category C (ie, not recommended for use during pregnancy unless the potential benefit justifies the potential risk to the fetus). METHODS: Three types of adverse events were studied: spontaneous abortion, fetal abnormality, and obstetric complications. Traditional evidence-based criteria were used to assess a search-protocol product of four clinical studies and two case reports. RESULTS: The single positive finding ("preterm delivery" without low birth weight) was in the smallest study; this study was retrospective and the finding was externally inconsistent with the other three larger studies, all of which were prospective. No study followed children for more than 4 years, which is the period needed to identify the maximum number of congenital anomalies. Rigorous teratological technique was generally not employed. Post hoc power calculations were used to provide parameters of the hazard detectable by these studies in aggregate. CONCLUSIONS: Pregnancy categories B and C both seem feasible for sumatriptan. Within the limits of the examined studies, there is no evidence for any specific effect of sumatriptan on pregnancy outcome. Patients inadvertently exposed to sumatriptan during an early stage of pregnancy should be reassured by these data.
Authors:
Anthony W Fox; Christina D Chambers; Philip O Anderson; Merle L Diamond; Egilius L H Spierings
Related Documents :
10886849 - Alcohol consumption and pregnancy in the mexican national addiction survey.
1955899 - Cocaine-related vascular headaches.
17565289 - Childhood neurobehavior disinhibition amplifies the risk of substance use disorder: int...
10956449 - Alcohol in pregnancy and neonatal outcome.
10940969 - The effect of lead on male fertility: a time to pregnancy (ttp) study.
7026219 - Epidemiological appraisal of the literature on the fetal alcohol syndrome in humans.
7959909 - Role of adrenal in establishment and development of conceptus in unilaterally ovariecto...
23852639 - The effect of ovarian stimulation on the outcome of intrauterine insemination.
9820259 - Moxibustion for correction of breech presentation: a randomized controlled trial.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Headache     Volume:  42     ISSN:  0017-8748     ISO Abbreviation:  Headache     Publication Date:  2002 Jan 
Date Detail:
Created Date:  2002-05-13     Completed Date:  2002-06-26     Revised Date:  2009-02-02    
Medline Journal Info:
Nlm Unique ID:  2985091R     Medline TA:  Headache     Country:  United States    
Other Details:
Languages:  eng     Pagination:  8-15     Citation Subset:  IM    
Affiliation:
EBD Group, Carlsbad, Calif 92009, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abnormalities, Drug-Induced
Abortion, Spontaneous / chemically induced
Evidence-Based Medicine / methods*
Female
Humans
Infant, Newborn
Infant, Premature
Obstetric Labor Complications / chemically induced
Pregnancy
Pregnancy Outcome*
Prospective Studies
Retrospective Studies
Serotonin Agonists / adverse effects*
Sumatriptan / adverse effects*
Chemical
Reg. No./Substance:
0/Serotonin Agonists; 103628-46-2/Sumatriptan
Comments/Corrections
Comment In:
Headache. 2004 Sep;44(8):842-3   [PMID:  15330843 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New paradigms in the recognition and acute treatment of migraine.
Next Document:  Oral magnesium load test in patients with migraine.